Welcome to our dedicated page for LABCORP HOLDINGS SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. (LH) hosted its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a detailed long-term outlook through 2029. For 2026, Labcorp continues to target enterprise revenue of $14.71–$14.83 billion, implying 5.4%–6.3% growth versus 2025, driven by Diagnostics Laboratories revenue of $11.45–$11.53 billion and Biopharma Laboratory Services revenue of $3.27–$3.30 billion. Adjusted EPS guidance remains $18.10–$18.55, up 10.1%–12.8% year over year, with free cash flow of $1.24–$1.36 billion. Labcorp also reiterated its 2026–2029 long-term framework of 5%–8% compound annual revenue growth, 8.5%–11.5% compound annual adjusted EPS growth, adjusted operating margin expansion of 75–150 basis points by 2029, and free cash flow growth in line with adjusted earnings, supported by technology-enabled efficiency programs and disciplined capital deployment.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Oyegunwa Akinbolade reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president, chief information officer and chief technology officer Akinbolade Oyegunwa received a grant of 750 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. After this award, Oyegunwa holds an aggregate of 2,940 Restricted Stock Units directly.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Meltzer Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president and chief operating officer Jonathan C. Meltzer received a grant of 900 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and will vest in three equal annual installments beginning on September 1, 2027.
After this grant, Meltzer holds an aggregate of 3,594 Restricted Stock Units, representing potential future shares of Labcorp common stock if the vesting conditions are satisfied.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Vaughn Bryan T reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Bryan T. Vaughn, EVP and President, Diagnostics, received a grant of 1,500 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. Following this award, Vaughn holds an aggregate of 5,204 Restricted Stock Units, all reported as directly owned.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Caveney Brian J reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Brian J. Caveney, EVP, President of BLS, CMO & CSO, received a grant of 3,000 Restricted Stock Units on September 1, 2026. Each unit represents a contingent right to receive one share of Labcorp common stock and vests in three equal annual installments beginning on September 1, 2027.
After this grant, Caveney holds a total of 7,170 Restricted Stock Units directly. No Rule 10b5-1 trading plan is reported in connection with this award.
Labcorp Holdings Inc. (LH) announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 11:30 a.m. ET. A live audio webcast will be accessible through Labcorp’s investor relations website and archived for 180 days.
Labcorp describes itself as a global provider of innovative and comprehensive laboratory services, with nearly 71,000 employees serving clients in about 100 countries, supporting more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performing over 750 million tests annually.
LABCORP HOLDINGS INC. director Kerrii B. Anderson reported selling 3,000 shares of common stock on 2026-08-17 at $318.02 per share in an open-market or private transaction made pursuant to a Rule 10b5-1 trading plan. After this sale, she held 6,563 shares directly and 144 shares indirectly in each of two separate trusts.
Labcorp Holdings Inc. (NYSE: LH) reported that it will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, CFO Julia Wang and other executives plan to present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session. A live webcast and subsequent replay with supporting materials will be available via the company’s investor relations website.
Labcorp describes itself as a global leader in laboratory services with nearly 71,000 employees serving clients in approximately 100 countries. It supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide.
Labcorp Holdings Inc. reports a leadership change in its laboratory services business. On August 11, 2026, Megan D. Bailey notified the company of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.
Effective September 1, 2026, Brian J. Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role, he will oversee both the Early Development Research Laboratories and Central Laboratories businesses.